Addressing these challenges will unlock a new era in cancer patient outcomes, focusing the impact of the rapidly expanding arsenal of therapies available to an oncologist on mutation-based combinations derived from expanded diagnostics.
Data driven decisions in cancer care
EMR- and biomarker-based diagnostics are now ubiquitous in oncology. But several factors hinder greater use of automation and analytics-driven decisions. This paper examines these limitations and suggests solutions.